Comparing two drug combinations for relapsed mantle cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study compares two oral targeted therapies (ICP-248 plus orelabrutinib vs. pirtobrutinib) for people with mantle cell lymphoma that has returned or stopped responding to treatment. It aims to see which combination works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have relapsed or refractory mantle cell lymphoma.
- You must have been treated with a BTK inhibitor (like ibrutinib) before.
- You must not have had a stem cell transplant within the last 3 months or ever had an allogeneic transplant.
- You must not have any other active cancer in the last 2 years.
- You must not have uncontrolled heart disease, bleeding disorders, or be on warfarin.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called ICP-248 for people with mantle cell lymphoma that has returned or not responded to previous treatments. It aims to see if the drug is safe and effective.
This study tests two different drug combinations for people with marginal zone lymphoma that has come back or stopped responding to previous treatment. One group gets orelabrutinib plus rituximab, and the other gets lenalidomide plus rituximab, to see which works better and has fewer side effects.
This trial tests two new oral medications (ICP-248 and Orelabrutinib) together as a first treatment for people with CLL or SLL. The goal is to see if this combination works better than current options and is safe for newly diagnosed patients.
This trial tests a new combination of drugs (orelabrutinib plus BR) compared to BR alone for people with newly diagnosed mantle cell lymphoma who have not had treatment before. It may be an option if you are older or not able to have a stem cell transplant.
This trial is testing a combination of two targeted drugs, orelabrutinib and rituximab, as a first treatment for mantle cell lymphoma (MCL). Some patients may also get a stem cell transplant. The goal is to see how well this approach works.
This trial tests adding the targeted therapy orelabrutinib (a BTK inhibitor) to standard chemotherapy (bendamustine) and immunotherapy (rituximab) for people with high-risk mantle cell lymphoma who have not had treatment before. The goal is to see if the combination works better at controlling the cancer.
Hear when a new Relapsed or Refractory Mantle Cell Lymphoma (MCL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.